Siemens Healthineers Stock Stuck in Spin-Off Limbo

Siemens AG's planned divestment of its 67% stake creates a major share overhang risk, suppressing the stock price despite operational initiatives and maintained guidance.

Investors in Siemens Healthineers are caught in a holding pattern, with the looming divestment of its majority owner overshadowing both operational progress and significant macroeconomic challenges. The stock, trading near €37.30, has shed roughly 16% since the start of the year, hovering dangerously close to its 52-week low as the market braces for a potential flood of new shares.

The core issue is Siemens AG's planned exit. The Munich-based parent currently holds a 67% stake in the medical technology firm and is actively evaluating a full separation. Advisors are reportedly assessing options ranging from a direct sale of shares to a distribution as a dividend to Siemens' own shareholders. This "overhang" risk—the prospect of a massive new supply of stock hitting the market—is the dominant force suppressing the share price, driving investor uncertainty.

This corporate uncertainty arrives at an inopportune time. The company is grappling with tangible financial headwinds. New US tariffs are expected to shave approximately €400 million off its adjusted EBIT this fiscal year. Simultaneously, revenue in its Chinese diagnostics business fell 3% in the first quarter, pressured by local anti-corruption measures and shifting procurement structures.

Against this difficult backdrop, management faces a critical test. At the HSBC Global Investment Summit in Hong Kong, investors are demanding concrete details on the spin-off plan. The company's self-imposed deadline for providing clarity falls early in the second quarter, adding urgency to the proceedings.

Operationally, the picture is mixed but shows strategic initiative. The company recently signed a clinical supply agreement in the US with Radiopharm Theranostics for the radiopharmaceutical RAD101, bolstering its position in precision medicine. It is also pushing expansion in key growth markets. In India, it is adding local production of the Artis One Edition X angiography system in Bengaluru to target price-sensitive hospitals. Furthermore, a new ten-year partnership with US provider Onvida Health in Arizona secures an order volume exceeding $100 million, over half of which is for new imaging and radiotherapy systems.

Despite the pressures, Siemens Healthineers maintains its full-year guidance, targeting comparable revenue growth of 5-6% and adjusted earnings per share between €2.20 and €2.40. However, analyst sentiment remains cautious. Goldman Sachs recently cut its price target on the stock from €52 to €45, citing persistent uncertainty over the future shareholder structure and ongoing diagnostics business challenges.

The path forward hinges on transparency. Concrete details on the separation are expected by the next quarterly report in May or potentially as soon as the Hong Kong summit. Until the scale and method of the placement are clear, the stock's upside potential remains severely capped, leaving investors to weigh strategic gains against the specter of a major share sale.